Uniper and Openlink Lead the Way in Tier-One Cloud ETRM Adoption
Openlink, the global leader in trading, treasury and risk management solutions for the energy, commodities, corporate and financial services industries, has announced a deal with the international energy company, Uniper based in Germany, to move its extensive energy trading and risk management (ETRM) systems into the Cloud. This marks the first fully public Cloud ETRM implementation for a company of Uniper’s size and prestige.
The 700-user deal will include two applications of Openlink’s system, covering front-to-back office trading and risk management support across Uniper’s asset classes including oil, gas, LNG and power.
Uniper has one of the world’s largest and most extensive energy trading portfolios, both to supply its broad fleet of generation assets and for proprietary trading purposes. Uniper’s goal is to migrate from its current hosting facility into a future ready, fully scalable and cost effective Cloud offering from Openlink.
Having worked with Openlink on other solutions for the past 15 years, and with a new five-year partnership agreement in place since 2016, Uniper already had a trusted partner in Openlink. The timing was also perfect: Openlink has invested heavily in bringing its award-winning systems to the Cloud and developing industry-leading expertise. This meant that Openlink was able to deliver the ideal solution to include Openlink Cloud, cloud management tools and ancillary services to fulfill Uniper’s requirements.
In a three-month proof of concept (POC) project between October 2016 and January 2017 it was demonstrated that the system could provide the required featureset, security and computing power while maintaining access to historical data.
The POC showed that a Cloud-based delivery could not only match current performance, but significantly improve it, for example by accelerating end of day batch processing along with allowing intra day calculations that would not have been possible on premise. The solution was also shown to lower the total cost of ownership by enabling Uniper to only pay for what it needed, scaling to suit requirements all this in combination with a sophisticated security stack and integration into the Uniper downstream systems.
As is typical for a utility of Uniper’s size, the existing system included highly customised physical and virtual components and bespoke user interfaces.
“There are a lot of challenges in recreating highly customised software ecosystems completely in the public Cloud,” says Rich Grossi, CEO at Openlink. “However, we’ve built a robust Cloud environment at Openlink and we’re confident it is up to the task. The fact that Uniper agrees is testament to the power of our Cloud offering.”
“Uniper is at the center of the global energy markets,” says Marco Scherer, SVP Sales and Trading IT at Uniper. “Our traders need the very best technology underpinning their actions to ensure we are always managing our risk responsibly. To be able to do so while reducing IT spend and increasing performance is a hugely attractive proposition. With Openlink Cloud, we will be able to even better support the Uniper Business activities and our future Business developments with this future proven, scalable and pay-per-use Cloud solution.”
For more than 25 years, Openlink (www.Openlink.com) has been providing trading, treasury and risk management solutions for the world’s most sophisticated commodity, energy, corporate and financial services organisations.
Openlink’s innovative solutions help clients break down organizational silos and instantaneously connects trading, risk and treasury across multiple asset classes and throughout the front, middle and back office. The Openlink Cloud platform, coupled with our advanced analytics, enables clients to manage huge data volumes, take advantage of even the most fleeting of market opportunities, and mitigate risk.
Openlink has topped Chartis’ RiskTech100 Energy Trading Risk Category for the last six years and been named a Leader in Gartner’s Trading Platforms Magic Quadrant. Other accolades include the Treasury Management International awards, Energy Risk awards and Central Banking awards.
Openlink is proud to support more than 38,000 users and more than 600 clients, including 12 of the world's largest commodity/energy companies, 9 of the largest financial institutions, and 13 central banks.
Liz Allen, +44 (0)79 0026 8478
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme